



Advancing research  
*saving lives*

## **Australia New Zealand Gynaecological Oncology Group**

ABN 69 138 649 028

**Annual Financial Report  
for the year ended 30 June 2025**

<b>CONTENTS</b>	<b>Page</b>
<b>DIRECTOR'S REPORT</b>	<b>3</b>
<b>AUDITOR'S INDEPENDENCE DECLARATION</b>	<b>9</b>
<b>STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME</b>	<b>10</b>
<b>STATEMENT OF FINANCIAL POSITION</b>	<b>11</b>
<b>STATEMENT OF CHANGES IN EQUITY</b>	<b>12</b>
<b>STATEMENT OF CASH FLOWS</b>	<b>13</b>
<b>NOTES TO AND FORMING PART OF THE FINANCIAL STATEMENTS</b>	<b>14</b>
<b>DIRECTOR'S DECLARATION</b>	<b>28</b>
<b>INDEPENDENT AUDITOR'S REPORT</b>	<b>29</b>

## **Directors' Report**

---

The Directors of Australia New Zealand Gynaecological Oncology Group (the company) submit their annual financial report for the year ended 30 June 2025.

### **Directors**

The following persons were Directors of the company during the year and up to the date of this report unless otherwise stated:

<b>Professor Clare Scott AM</b> <b>ANZGOG Chair</b>	Clare Scott AM is a Medical Oncologist at the Peter MacCallum Cancer Centre and the Royal Melbourne and Royal Women's Hospitals and is Joint Head, Clinical Discovery and Translation and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research and Professor of Gynaecological Cancer at University of Melbourne. She has over 20 years' experience in treating breast and ovarian cancer and in clinical cancer genetics in Familial Cancer Clinics. Clare has been Principal Investigator for more than ten ovarian cancer clinical trials of targeted therapy leading to high impact publications and is immediate past Chair of the ANZGOG OASIS Initiative Steering Committee. In the lab, Clare has developed new ovarian cancer pre-clinical models and is using genomics to study targeted drug combinations to combat drug resistance. Clare has established a rare cancer research program to improve access to targeted treatments for patients diagnosed with a rare cancer. Clare was awarded the Sir Edward Dunlop Cancer Research Fellowship from Cancer Council Victoria (2012) and a Clinical Research Fellowship from the Victorian Cancer Agency (2018).
<b>Fiona Erhardt</b> <b>Non-Executive Finance Director</b>	Fiona is a chartered accountant, CA, and joined the ANZGOG Board as Finance Director in May 2021. Fiona started her career with professional services firm Ernst & Young where she spent 10 years in the Audit Division in Sydney and London. Moving to senior finance roles in ASX listed Corporates for 17 years Fiona was able to navigate complex business structures and acquisitions to simplify financial reporting and provide insightful information to stakeholders. More recently Fiona has held CFO roles at not-for-profit organisations. Fiona brings strong corporate governance and risk management experience. Her ability to explain financial concepts in operational language and empower people to understand and use financial information drives better decision making. Known for her trust and integrity Fiona's guidance helps boards and executives manage financial risk. Fiona is an Audit Committee member for the Inspector-General of Taxation and Taxation Ombudsman (IGTO) and is the Chair of the ANZGOG Audit Risk and Compliance Committee.
<b>Professor Paul Cohen</b> <b>Chair, Research Advisory Committee</b>	Paul Cohen is a Consultant at the Western Australian Gynaecological Cancer Service, King Edward Memorial Hospital and Clinical Professor at the University of Western Australia. Paul's research interests include prediction of histological tumour regression in women with high-grade serous ovarian cancer following neoadjuvant chemotherapy, the supportive care of women affected by gynaecological cancers, and gynaecological cancer epidemiology. Paul is the current chair of the ANZGOG Research Advisory Committee, Chair of the International Gynecological Cancer Society (IGCS) Education Committee, and a Board Director of the IGCS. Paul is a member of the eviQ Cancer Genetics Reference Committee, and a member of the Editorial Boards of the International Journal of Gynecological Cancer and Scientific Reports.

**Australia New Zealand Gynaecological Oncology Group**  
**Annual Financial Report**  
**For the year ended 30 June 2025**

<b>Dr Michelle Wilson</b> <b>New Zealand Director</b>	Michelle Wilson is a medical oncologist who subspecialises in gynaecological cancers and early-phase clinical trials. She is the clinical director for Cancer and Blood Research at Auckland City Hospital. Dr Wilson is a very active researcher and is also one of 4 Principal Investigators with the early phase Auckland Cancer Trials Centre. Dr Wilson’s research focus is geared towards early phase translational studies and clinical trial endpoints, in particular their utility and evolution in the era of precision oncology. She was awarded a medical doctorate on this topic in 2018 through the University of Auckland. Dr Wilson is a member of the Ovarian Tumour Working Group, the ANZGOG Research Advisory Committee, and the OASIS Steering. She is New Zealand Director for ANZGOG.
<b>Associate Professor Philip Beale</b> <b>(resigned 22 October 2024)</b>	Philip Beale is a medical oncologist at Concord Hospital and Associate Professor at the University of Sydney. He has a special interest in ovarian, breast, colorectal and upper gastrointestinal cancers and is involved in Phase I, II and III clinical trials for all of these cancers and is the PI in several breast and ovarian cancer trials. He has published more than 100 peer reviewed papers. He is the immediate past Chair of ANZGOG and is a member of the AGITG and ANZBCTG trials groups. He is a member and past Chair of the ANZGOG Ovarian Tumour Working Group, is on the ANZGOG Research Advisory Committee, the TR-ANZGOG Steering Committee and is a member of the AGITG and ANZBCTG trials groups.
<b>Professor Alison Brand AM</b>	Alison Brand AM is a gynaecological oncologist and Director of the Department Gynaecological Oncology at Westmead Hospital, Sydney. She holds the academic title of Clinical Professor at the University of Sydney and is immediate Past-Chair of Gynaecological Cancer Intergroup and past Chair of the Australia New Zealand Gynaecological Oncology Group (ANZGOG). She was awarded Member, Order of Australia in 2021 for “significant service to medicine, to gynaecology and to medical organisations”. Prof Brand has held a number of advisory and/or board positions with national and international gynaecological cancer organisations, including Cancer Australia, the Clinical Oncology Society of Australia and the Gynaecological Cancer Intergroup (GCIG) and has helped draft a number of national gynaecological cancer guidelines. She has a particular interest in development and implementation of surgical trials and pragmatic trials, and in the development and benchmarking of clinical quality indicators in gynaecological oncology.
<b>Associate Professor Alison Davis</b>	Alison Davis is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Clinical Associate Professor at the Australian National University. She has extensive clinical experience with sub-speciality expertise in gynaecological and breast malignancies. Her main research focus is Quality of Life (QOL) and End of Life (EOL) care in women with gynaecological malignancies. Alison is the immediate past Chair of the ANZGOG Research Advisory Committee, from 2017 to February 2023, is a member of the Research Management Group, the OASIS and TR-ANZGOG Steering Committees and the Ovarian Tumour Working Group and is also a director of the ANZGOG Board. She is currently also a member of the ACT HREC clinical trial subcommittee, ACT SE NSW Breast Cancer Treatment Group and Australian Breast Cancer Tissue Bank.
<b>Associate Professor Pearly Khaw</b>	Associate Professor Pearly Khaw is currently the lead Radiation Oncologist in Gynaecological Oncology at the Peter MacCallum Cancer Centre. She has over 20 years of experience in radiation oncology, 18 of those years specialising in the management of gynaecological cancer patients. She is a clinician-researcher and is actively involved in ANZGOG, and is a member of the Audit Risk and Compliance Committee, EDEN Steering Committee and the Uterine Tumour Type Working Group. She is the current IGCS (International Gynecology Cancer Society) Radiation Oncology Education Chair, a member of the Editorial Board of the IJGC (International Journal of Gynaecological Cancer) and Associate Editor (Gynae-Oncology) for JMIRO (Journal of Medical Imaging and Radiation Oncology). She was previously the Deputy Chair of the Treatment Sub-Advisory Group for the National Cervical Cancer Elimination Strategy (Australia), and is currently involved in the updating of the Optimal Care Pathway for Cervical Cancer.

**Australia New Zealand Gynaecological Oncology Group**  
**Annual Financial Report**  
**For the year ended 30 June 2025**

---

**Associate Professor Yoland Antill**  
**(appointed 5 March 2025)**

Associate Professor Yoland Antill is a Medical Oncologist and Cancer Genetics specialist based at Cabrini Health, Frankston Hospital and Royal Melbourne Hospital in Victoria. She holds an adjunct clinical position in the Faculty of Medicine, Dentistry and Health Sciences at Monash University. While trained at the University of Newcastle and Royal North Shore in Sydney, NSW, she now calls Melbourne home. A/Prof Antill's working and research interests are in the management of Gynaecological and Breast cancers together with Hereditary Cancer Syndromes. She is the current Deputy Chair of ANZGOG Research Advisory Committee, Lead of EDEN's Adjuvant and Metastatic Therapies Focus Group, a member of ANZGOG's EDEN Steering Committee and ex-officio of the ANZGOG Uterine Tumour Working Group. She also is a member of Australia's Breast Cancer Trials Group, the Medical Oncology Group of Australia and the American Society of Clinical Oncology. A/Prof Antill has published widely in the areas of hereditary cancer risk breast and gynaecological cancers and is regularly invited to speak at national and international meetings. She is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical and supportive care trials. A/Prof Antill has more than 20 years' experience in both medical oncology and in the diagnosis and management of hereditary cancer syndromes.

---

**Ms Donna Long**

Donna Long is currently the Manager of the Regional Trials Network – Victoria. The Network membership includes 8 Clinical Trials Units in Regional Victoria and manages Government funded projects like the Regional Victorian Trials alliance: Linkages, Innovation, Special populations, Equity (ReViTALISE) project. Donna has had a long history in the oncology sector starting in nursing while training at the Royal Prince Alfred Hospital. Donna has over 35 years' experience in Oncology including 12 years in the Gynaecological Oncology surgical unit at The Royal Hospital for Women in Sydney and 13 years' experience as a Research Nurse/Study Coordinator at Border Medical Oncology Research Unit in Albury. Donna's experience includes Palliative Care at Sacred Heart Hospice in Sydney, Breast Cancer Peer Support Coordinator at the Cancer Council NSW, and experience as a Service Improvement Facilitator for the Hume Regional Integrated Cancer Service. Donna has been a member of ANZGOG and the study coordinators committee since 2006 and is a past Chair of the ANZGOG Study Coordinators Committee from 2020 - 2023.

---

**Associate Professor Tarek Meniawy**

Tarek Meniawy is a medical oncologist who subspecialises in melanoma, gynaecological cancers as well as early-phase clinical trials. He is an Adjunct Associate Professor at Edith Cowan University and a Clinical Associate Professor at the University of Western Australia, where he was awarded a PhD degree in 2016. He is also a Principal Investigator at Linear Clinical Research, the only dedicated Phase I clinical trial unit in Western Australia, and one of a handful of such dedicated units in Australia. Dr Meniawy is the immediate past Chair of the OASIS Steering Committee and a member of the ANZGOG Research Advisory Committee and the Ovarian Tumour Working Group.. He is also a member of the statewide Western Australia Gynaecologic Cancer Service (WAGCS), as well as the WA Kirkbride Melanoma Advisory Service.

---

**Company Secretary**  
**Ms Alison Evans**

Ms Alison Evans, Chief Executive Officer for ANZGOG, also acts as Company Secretary. Alison Evans has been Chief Executive Officer and Company Secretary for ANZGOG since 2012. She has a background as both Chief Executive and Company Secretary of not-for-profit organisations and Company Director in management consulting. Her education has been in business management and marketing. Prior to her work in not-for-profits Alison worked in Australia and New Zealand in national marketing and communications management roles including media and technology companies.

---

### Meetings of Directors

During the year, seven meetings of directors were held. Attendance by each director was as follows:

Director	Eligible to Attend	Attended
Clare Scott (Chair)	7	7
Philip Beale (resigned 22 October 2024)	3	2
Alison Brand	7	5
Paul Cohen	7	6
Alison Davis	7	6
Fiona Erhardt	7	7
Pearly Khaw	7	7
Yoland Antill (appointed 5 March 2025)	1	1
Donna Long	7	7
Tarek Meniawy	7	4
Michelle Wilson (NZ)	7	4

### Principal activity

---

The principal activity of the company is to conduct and promote clinical trials and multidisciplinary research into the causes, prevention and treatment of gynaecological cancers, improving outcomes and quality of life.

### Vision (our ambition)

---

Advancing research, saving lives.

### Values

---

- **Excellence:** we are committed to world-class standards, innovation and best practice across all aspects of our research and organisation.
- **Impact:** our research is driven by evidence of need and an ambition to change practice, improve outcomes and provide hope.
- **Equity:** we are inclusive and strive to enable access to and benefit from our research for all.
- **Collaboration:** we recognise the value of working together and encourage cooperation.
- **Openness:** we are transparent and fair in all aspects of our governance and operations.

### Strategic Goals 2023–2028

---

1. **CATALYSE** innovative, practice-changing cooperative gynaecological cancer research.
2. **EXPAND** the reach, relevance and impact of our research.
3. **ENGAGE**, collaborate and share expertise and insights.
4. **SUSTAIN** a vibrant and efficient research organisation.

## **Clinical Trials Program**

---

ANZGOG meets its goals through conducting independent investigator initiated clinical trials, ensuring these trials are widely accessible to patients, creating strong links locally and globally, engaging professional disciplines at all levels of protocol development and implementation, and securing funding to support clinical research education.

ANZGOG gratefully acknowledges the partial or full support provided for its trials by:

- Industry
- Medical Research Future Fund
- National Health and Medical Research Council
- Cancer Australia
- University of Sydney NHMRC Clinical Trials Centre
- Trusts and Foundations
- Donors

ANZGOG also collaborates with institutions and researchers and with other national Cancer Cooperative Clinical Trials Groups in Australia and New Zealand. International collaborations include:

- GCIG – Gynaecological Cancer InterGroup
- APGOT – Asia Pacific Gynecologic Trials group
- ENGOT – European Network of Gynecological Oncology Trials
- NRG – National Research Group USA
- CCTG – Canadian Cancer Trials Group
- CRUK - Cancer Research UK located in London, UK;
- GINECO - Groupe des Investigateurs Nationaux pour l'Etude des Cancers de l'Ovaire et du sein
- NUHS – National University Hospital Singapore
- NSGO – Nordic Society of Gynaecologic Oncology
- IRCCS MaNGO – Istituto di Ricerche Farmacologiche, Mario Negri Gynecologic Oncology group
- NOGGO - North-Eastern-German Society of Gynaecological Oncology

ANZGOG activity to develop new research is supported by the Cancer Australia 'Support for Cancer Clinical Trials Program' grant.

ANZGOG trials are conducted independently with ANZGOG as trial sponsor. It also conducts gynaecological cancer trials through a collaboration with the University of Sydney NHMRC Clinical Trials Centre with the University of Sydney acting as the sponsor and receiver of the funds for these collaborative trials. The funds for these collaborative trials are not reported in the financial accounts for ANZGOG except for minor support activities undertaken by ANZGOG.

### **Education Activities**

Developing skills of members, trainees and others working in gynaecological cancer is an important activity for ANZGOG. Education activities in 2025 included the Annual Scientific Meeting, a two-day conference and a day of specialty workshops, and the Foundations Series in Gynaecological Cancer webinars focused on cervical and vulvar cancer. A Preceptorship in cervical cancer was also conducted. In addition, ANZGOG takes advantage of collaborative education activities to broaden members skills.

### **Publications**

Publication of results is an important measure of impact for clinical trial outcomes. There were 14 papers published in scientific journals in the year bringing the total number of published papers for ANZGOG clinical trials to 249.

### **Fundraising**

Fundraising for clinical trials, ideas and innovation grants, and education is conducted by ANZGOG's  fundraising unit. For more information on fundraising activities refer to Note 20.

### **Performance measurement**

ANZGOG measures its performance to its 5-year strategic plan and performance measures annually. These outcomes are reported in its Annual Report which is posted on its website and available to all members and the public. Performance against the Annual Business Plan and Budget is reviewed monthly. Individual special initiatives are measured against their plans and budgets.

### **Review of operations**

The company's net surplus/(deficit) for the year ended 30 June 2025 was (\$710,686) deficit (2024: \$66,133 surplus). As at 30 June 2025 the company had net assets of \$3,621,753 (2024: \$4,332,439).

The financial report has been prepared on a going concern basis. Given the company's net assets and the funding agreements for clinical trials, philanthropy and grants, the company will be able to pay its debts as and when they become due and payable and, as such, it is appropriate to prepare the accounts on a going concern basis.

### **Changes in state of affairs**

In the opinion of the directors there were no significant changes in the state of affairs of the Group that occurred during the financial year under review

### **Subsequent events**

No matters or circumstance has arisen since the end of the year that have significantly affected, or may significantly affect, the operations of the company, the results of these operations, or the state of affairs of the company in future years.

### **Future developments**

Likely developments in the operations of the company and the expected results of those operations in future years have not been included in this report as the inclusion of such information is likely to result in unreasonable prejudice to the company. Accordingly, this information has not been disclosed in this report.

Signed in accordance with a resolution of the Board of Directors

On behalf of the directors



Professor Clare Scott AM  
Chair

Sydney, 25 September 2025

## AUDITOR'S INDEPENDENCE DECLARATION

As auditor for the audit of Australia New Zealand Gynaecological Oncology Group for the year ended 30 June 2025, I declare that, to the best of my knowledge and belief, there have been:

- i) no contraventions of the independence requirements of the *Australian Charities and Not-for-profits Commission Act 2012* in relation to the audit; and
- ii) no contraventions of any applicable code of professional conduct in relation to the audit.



.....  
Jason Croston, **FCA**

Registered Company Auditor

**SRJ Walker Wayland (Audit Services) Pty Ltd**

Dated: 10 October 2025

### **Brendale**

Unit 3, 27 South Pine Rd  
Brendale, QLD 4500  
**+61 (7) 3490 9988**

### **Sunshine Coast**

Level 2, 2 Innovation Parkway  
Birtinya, QLD 4575  
**+61 (7) 5301 9957**

### **Brisbane**

Level 11, 300 Ann Street  
Brisbane, QLD 4001  
**+61 (7) 3490 9988**

**Australia New Zealand Gynaecological Oncology Group**

Annual financial report - 30 June 2025

**Statement of profit or loss and other comprehensive income  
for the year ended 30 June 2025**

	<b>Note</b>	<b>2025</b> <b>\$</b>	<b>2024</b> <b>\$</b>
Revenue from continuing operations	3	5,051,244	4,495,197
Trial Expenses		(1,054,972)	(560,250)
Administration Expenses		(445,015)	(352,115)
Finance Expenses		(40,217)	(36,854)
Depreciation & Amortisation Expense		(20,611)	(22,687)
Occupancy Expenses		(90,138)	(46,519)
Travel Expenses		(92,369)	(96,917)
Employee Benefit Expenses		(2,648,349)	(2,539,972)
Conference expense		(335,046)	(364,703)
Fundraising Expenses		(275,664)	(146,629)
Communications & Education		(297,470)	(157,536)
<b>Surplus/(Deficit) for the year from Operations</b>		<b>(248,607)</b>	<b>171,015</b>
Project and Grant expenses utilising ANZGOG reserves	14	(779,298)	(413,399)
Net change in fair value of financial assets at fair value through profit or loss		317,219	308,517
<b>Profit/(Loss) before income tax expense</b>		<b>(710,686)</b>	<b>66,133</b>
Income tax expense		-	-
<b>Net profit for the year</b>		<b>(710,686)</b>	<b>66,133</b>
Other comprehensive income		-	-
<b>Total comprehensive income/(loss) for the year</b>		<b>(710,686)</b>	<b>66,133</b>

The accompanying notes form part of these financial statements.

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Statement of financial position

as at 30 June 2025

	Note	2025 \$	2024 \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash and cash equivalents	4	316,635	986,042
Trade and other receivables	5	708,143	148,511
Total current assets		<u>1,024,778</u>	<u>1,134,553</u>
<b>Non-current assets</b>			
Fixed assets	6	18,624	16,622
Intangible assets	7	31,390	41,508
Other financial assets	8	5,761,172	5,772,499
Total non-current assets		<u>5,811,186</u>	<u>5,830,629</u>
<b>Total assets</b>		<u>6,835,964</u>	<u>6,965,182</u>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Trade and other payables	9	646,338	378,651
Deferred income	10	2,323,704	2,047,056
Employee benefits	13	199,871	173,380
Total current liabilities		<u>3,169,913</u>	<u>2,599,087</u>
<b>Non-Current liabilities</b>			
Employee benefits	13	44,298	33,656
Total non-current liabilities		<u>44,298</u>	<u>33,656</u>
<b>Total liabilities</b>		<u>3,214,211</u>	<u>2,632,743</u>
<b>Net assets</b>		<u>3,621,753</u>	<u>4,332,439</u>
<b>Equity</b>			
New Research Fund reserve	14	270,886	452,726
Beneficiary Fund reserve	14	348,948	346,434
OASIS Initiative reserve	14	796,233	1,315,988
Retained surplus	14	2,205,686	2,217,291
<b>Total equity</b>		<u>3,621,753</u>	<u>4,332,439</u>

The accompanying notes form part of these financial statements.

**Australia New Zealand Gynaecological Oncology Group**

Annual financial report - 30 June 2025

**Statement of changes in equity  
for the year ended 30 June 2025**

Note	Fund for New Research reserve \$	Beneficiary Fund reserve \$	OASIS Initiative reserve \$	Retained surplus \$	Total \$
<b>Balance at 1 July 2023</b>	471,946	366,586	1,609,387	1,818,387	4,266,306
Transfer to reserves	-	80,628	-	(80,628)	-
Transfer from reserves	(19,220)	(100,780)	(293,399)	413,399	-
(Deficit)/Surplus for the year	-	-	-	66,133	66,133
<b>Balance as at 30 June 2024</b>	<u>452,726</u>	<u>346,434</u>	<u>1,315,988</u>	<u>2,217,291</u>	<u>4,332,439</u>
<b>Balance at 1 July 2024</b>	452,726	346,434	1,315,988	2,217,291	4,332,439
Transfer to reserves	(23,897)	104,114	-	(80,217)	-
Transfer from reserves	(157,943)	(101,600)	(519,755)	779,298	-
(Deficit)/Surplus for the year	-	-	-	(710,686)	(710,686)
<b>Balance as at 30 June 2025</b>	<u>270,886</u>	<u>348,948</u>	<u>796,233</u>	<u>2,205,686</u>	<u>3,621,753</u>

The accompanying notes form part of these financial statements.

**Australia New Zealand Gynaecological Oncology Group**

Annual financial report - 30 June 2025

**Statement of cash flows**

for the year ended 30 June 2025

	2025	2024
Note	\$	\$
<b>Cash flows from operating activities</b>		
Receipts from grants	2,040,829	2,818,339
Receipts from donations	837,617	635,480
Receipts from sponsorships, ASM and other revenue	1,665,486	1,156,674
Payments to suppliers and employees	(5,729,629)	(4,866,738)
<b>Net cash (outflow)/inflow from operating activities</b>	<u>(1,185,697)</u>	<u>(256,245)</u>
<b>Cash flows from investing activities</b>		
Payment for property, plant and equipment	(12,494)	(12,036)
Dividend income from investments	27,995	107,146
Payment for investments	-	(300,000)
Receipts from sale of investment	500,000	-
Interest received	789	7,076
<b>Net cash (outflow)/inflow from investing activities</b>	<u>516,290</u>	<u>(197,814)</u>
<b>Net increase / (decrease) in cash held</b>	(669,407)	(454,059)
<b>Cash at the beginning of financial year</b>	<u>986,042</u>	<u>1,440,101</u>
<b>Cash at the end of financial year</b>	4 <u>316,635</u>	<u>986,042</u>

The accompanying notes form part of these financial statements.

**Australia New Zealand Gynaecological Oncology Group**  
**Annual financial report - 30 June 2025**  
**Notes to and forming part of the financial statements**  
**for the year ended 30 June 2025**

**1 Summary of significant accounting policies**

**(a) Basis of preparation**

These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards - Simplified Disclosures issued by the Australian Accounting Standards Board ("AASB"), the Australian Charities and Not-for-profits Commission Act 2012, Charitable Fundraising Act 1991 (NSW) and associated regulations and the Corporations Act 2001, as appropriate for not-for-profit oriented entities.

The Company is a not-for-profit entity and incorporated Company limited by guarantee domiciled in Australia.

*AASB 1060 General Purpose Financial Statements - Simplified Disclosures for For-Profit and Not-for-Profit Tier 2 Entities*

The company has adopted the AASB 1060 from 1 July 2021. The standard provides a new Tier 2 reporting framework with simplified disclosures that are based on the requirements of IFRS for SMEs. As a result, there is increased disclosure in these financial statements for key management personnel and related parties. The adoption of the standard has not had a significant impact on the company.

The financial report has been prepared on an accruals basis (except for the cash flow information and as noted in 1 (d)(i)) and is based on historical costs and does not take into account changing money values or, except where specifically stated, current valuations of non-current assets.

The following material accounting policies, which are consistent with the previous period have been adopted in the preparation of this report.

All amounts are in Australian dollars.

**Going concern**

The directors believe that the going concern basis is appropriate for the preparation and presentation of the financial statements, notwithstanding the net current liabilities of \$2,145,135 (2024: \$1,464,534), negative operating cashflows of \$1,185,697 (2024: negative \$256,245), and deficit from operations of \$248,607 (2024: surplus \$171,015), the company has financial assets that are classified as non-current assets of \$5,761,172 that can be sold as and when required. The Directors believe that the Company has sufficient access to cash to continue operations, and the ability to pay creditors as and when they fall due.

## **Australia New Zealand Gynaecological Oncology Group**

**Annual financial report - 30 June 2025**

**Notes to and forming part of the financial statements**

### **1. Summary of significant accounting policies (continued)**

#### **(b) New, Revised or Amended accounting standards and interpretations adopted**

No new, revised or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board (AASB) have been adopted during the current reporting period.

The following Accounting Standards and Interpretations are most relevant to the company:

#### **(c) Plant & equipment**

Computers and Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

The depreciation rate used for each class of plant and equipment is as follows:

Computers - 33% straight line method

Plant and equipment - 20% straight line method

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of plant and equipment is derecognised upon disposal or when no further future economic benefit to the company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss.

**Australia New Zealand Gynaecological Oncology Group**  
**Annual financial report - 30 June 2025**  
**Notes to and forming part of the financial statements**  
**for the year ended 30 June 2025**

**1. Summary of significant accounting policies (continued)**

**(d) Intangible assets**

Acquired website and trademark has been initially capitalised at cost, which includes the purchase price (net of any discounts and rebates) and other directly attributable cost of preparing the asset for its intended use.

These costs are capitalised as an asset only when technical feasibility of the project is demonstrated, the organisation has an intention and ability to complete and use the asset to generate revenue and the costs can be measured reliably.

The website is subsequently carried at cost less accumulated amortisation and accumulated impairment losses. These costs are amortised to profit or loss using the straight-line method over ten years.

**(e) Cash and cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions and other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash which are subject to an insignificant risk of changes in value.

**(f) Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

## 1. Summary of significant accounting policies (continued)

### (g) Trade and other receivables

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any provision for expected credit loss. Trade receivables are generally due for settlement within 30 days.

Collectability of trade receivables is reviewed on an ongoing basis. Debts which are known to be uncollectable are written off by reducing the carrying amount directly. A provision for expected credit loss of trade receivables is raised when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Other receivables are recognised at amortised cost, less any provision for impairment.

### (h) Financial Assets

The Company classifies all of its financial assets as fair value through profit or loss (FVTPL).

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows. Management determines the classification of financial assets at initial recognition.

Financial assets at fair value through profit or loss (FVTPL)

Financial assets that do not meet the criteria for amortised cost or FVOCI are measured at FVTPL. Net gains or losses, including interest or dividend income, are recognised in profit or loss.

#### Fair Value Measurement

The Company's financial assets at fair value through profit or loss are measured using quoted prices in active markets (Level 1 inputs under the fair value hierarchy). The carrying amount of these financial assets approximates their fair value.

#### Financial Risk Management

The Company is exposed to market risk through movements in the fair value of its financial assets at FVTPL. These investments are traded in active markets, and the risk is managed by regular monitoring of portfolio performance.

The Company is not exposed to significant credit risk or liquidity risk in respect of these financial assets.

## Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

### 1. Summary of significant accounting policies (continued)

#### (i) Trade and other payables

These amounts represent liabilities for goods and services provided to the company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

#### (j) Employee benefits

##### *Short-term employee benefits*

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liability is settled.

##### *Other long-term employee benefits*

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit

#### (k) Goods and Services tax (GST)

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the taxation authority. In this case it is recognised as part of the cost of acquisition of the asset or as part of the expense.

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the taxation authority is included with other receivables or payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the taxation authority, are presented as operating cash flow.

## **Australia New Zealand Gynaecological Oncology Group**

**Annual financial report - 30 June 2025**

**Notes to and forming part of the financial statements  
for the year ended 30 June 2025**

### **1. Summary of significant accounting policies (continued)**

#### **(I) Revenue**

##### **(i) Grants**

Revenue from government grants received under enforceable agreements, where there are sufficiently specific performance obligations imposed, is deferred until the obligations are satisfied. If the performance obligations are not sufficiently specific, revenue will be recognised upon receipt.

Capital grants are recognised as income when (or as) it satisfies its obligations under the transfer. Capital grants are types of grants where the Company receives a financial asset to acquire or construct a non-financial asset to identified specifications; retains control of the nonfinancial asset (i.e. for its own use); and the transaction is enforceable.

##### **(ii) Revenue from contracts with customers**

Revenue is recognised at an amount that reflects the consideration to which the company is expected to be entitled in exchange from transferring goods or services to a customer. For each contract with a customer, the Company: identifies the contract with a customer; identifies the performance obligations in the contracts; determines the transaction price which takes into account estimates of variable consideration and the time value of money; allocates the transaction price to the separate performance obligations on the basis of the relative stand-alone selling price of each distinct good or service to be delivered; and recognises revenue when or as each performance obligation is satisfied in a manner that depicts the transfer to the customer of the goods or services promised.

##### **(iii) Bequests and donations**

ANZGOG, in common with most organisations dependent upon contributions, is unable to establish absolute control over all voluntary donations, due to their nature, prior to their initial entry into the accounting records. Therefore, revenue from fundraising, including donations and bequests, is recognised when received or receivable.

##### **(iv) Annual Scientific Meeting**

The Company contracts a professional Events Co-ordinator to manage the staging of the Annual Scientific Meeting including the receipt of revenue and payment of expenses in relation to the event. Documents detailing the income and expenses have been received from the Events Co-ordinator together with a reconciling statement.

##### **(v) Other revenue**

Other revenue is recognised when it is received or when the right to receive payment is established.

## Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

### Notes to and forming part of the financial statements for the year ended 30 June 2025

#### 2 Critical accounting judgements, estimates and assumptions

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts in the financial statements. Management continually evaluates its judgements and estimates in relation to assets, liabilities, contingent liabilities, revenue and expenses. Management bases its judgements, estimates and assumptions on historical experience and on other various factors, including expectations of future events, management believes to be reasonable under the circumstances. The resulting accounting judgements and estimates will seldom equal the related actual results. The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities (refer to the respective notes) within the next financial year are discussed below.

##### *Estimation of useful lives of assets*

The company determines the estimated useful lives and related depreciation and amortisation charges for its plant and equipment. The useful lives could change significantly as a result of technical innovations or some other event. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete or non-strategic assets that have been abandoned or sold will be written off or written down.

##### *Employee benefits provision*

As discussed in note 1(j), the liability for employee benefits expected to be settled more than 12 months from the reporting date are recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

##### *Determining whether a grant contains enforceable and sufficiently specific obligations*

The interaction between AASB 15 and AASB 1058 require management to assess whether the government grants and other funding received need to be accounted for under AASB 15 or AASB 1058. Key to this assessment is whether the government grants and other funding agreements contain:

- a contract with a customer that creates 'enforceable' rights and obligations, and
- the contract includes 'sufficiently specific' performance obligations.

Critical judgement was applied by management in assessing whether a promise is 'sufficiently specific', taking into account all facts and circumstances and any conditions specified in the arrangement (whether explicit or implicit) regarding the promised goods or services, including conditions regarding:

- the nature or type of the goods or services
- the cost or value of the goods or services
- the quantity of the goods or services
- the period over which the goods or services must be transferred.

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

	2025	2024
	\$	\$
<b>3 Revenue &amp; other income</b>		
<b>From continuing operations</b>		
Government grant	808,263	836,656
Trial Projects	2,178,339	1,904,340
Philanthropic grant	59,287	104,528
Fundraising activities	888,698	679,861
Corporate sponsorship	450,700	312,612
Annual Scientific Meeting Conference	426,187	350,200
Interest Income	789	7,076
Dividend Income	238,981	299,924
<b>Total Revenue &amp; other income</b>	<b><u>5,051,244</u></b>	<b><u>4,495,197</u></b>
<i>Timing of revenue recognition</i>		
Point in time (AASB 1058)	1,765,585	1,342,673
Over time (AASB 15)	<u>3,045,889</u>	<u>2,845,524</u>
	<u>4,811,474</u>	<u>4,188,197</u>
Other standards	<u>239,770</u>	<u>307,000</u>
	<u>5,051,244</u>	<u>4,495,197</u>
<b>4 Cash and cash equivalents</b>		
Cash at bank and on hand	316,635	986,042
	<u>316,635</u>	<u>986,042</u>

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

	<b>2025</b>	<b>2024</b>
	<b>\$</b>	<b>\$</b>
<b>5 Trade and other receivables</b>		
Trade Receivables	601,943	57,722
Rental Bond	2,763	2,763
Prepayments	103,437	88,026
	<u>708,143</u>	<u>148,511</u>
<b>6 Fixed assets</b>		
Office Equipment - at cost	11,669	11,669
Office equipment - accumulated	(11,588)	(11,218)
Computer Equipment - at cost	89,831	77,380
Computer Equipment - accumulated depreciation	(71,288)	(61,209)
	<u>18,624</u>	<u>16,622</u>
<i>Movements in carrying amounts</i>		
Carrying amount at beginning of year	16,622	17,155
Additions	12,494	12,035
Depreciation expense	(10,492)	(12,568)
	<u>18,624</u>	<u>16,622</u>

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

	2025	2024
	\$	\$
<b>7 Intangible assets</b>		
Website - at cost	22,056	22,056
Trademark - at cost	79,040	79,040
Intangibles - accumulated amortisation	(69,706)	(59,588)
	<u>31,390</u>	<u>41,508</u>
<i>Movements in carrying amounts</i>		
Carrying amount at beginning of year	41,508	51,627
Additions	-	-
Amortisation of Intangible Assets	(10,118)	(10,119)
	<u>31,390</u>	<u>41,508</u>
<b>8 Financial assets through profit or loss</b>		
Opening balance	5,772,499	5,006,726
Additions/(Withdrawals)	(500,000)	300,000
Net change in fair value	317,219	308,517
Other movements	171,454	157,256
Closing balance	<u>5,761,172</u>	<u>5,772,499</u>

Fair value of investment financial assets is based on quoted market prices for listed shares and are deemed to be Level 1 as per the fair value hierarchy.

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

	2025	2024
	\$	\$
<b>9 Trade and other payables</b>		
Trade Payables	252,130	131,238
Other Payables and Accruals	392,128	231,593
GST Payables	2,080	15,820
	<u>646,338</u>	<u>378,651</u>

## 10 Deferred Income

Deferred Income	2,323,704	2,047,056
	<u>2,323,704</u>	<u>2,047,056</u>

Funds held in Deferred Income are committed to fulfil specific performance obligations in relation to clinical trials and other ANZGOG projects including:

DOMENICA, XPORT42, TAPER, EPOCH, ENDEAR, ITTACc, VIP, MOCCA, iPRIME, PRECISE, IGNITE, SOLACE2, TR-ANZGOG, Survivors Teaching Students.

## 11 Remuneration of auditors

Audit of the financial report	12,000	11,000
Audit of grant acquittals	3,000	3,000
	<u>15,000</u>	<u>14,000</u>

## 12 Key management personnel disclosures

The aggregate compensation made to directors and other members of key management personnel of the company is set out below:

Key management personnel compensation	<u>235,586</u>	<u>222,232</u>
---------------------------------------	----------------	----------------

During the financial year the aggregate donations made by key management personnel amounts to \$40,042 (2024: \$0).

**Australia New Zealand Gynaecological Oncology Group**  
**Annual financial report - 30 June 2025**  
**Notes to and forming part of the financial statements**  
**for the year ended 30 June 2025**

	2025	2024
	\$	\$
<b>13 Employee benefits</b>		
Aggregate liability for employee benefits, including on-costs		
Current	199,871	173,380
Non-current	44,298	33,656
	<u>244,169</u>	<u>207,036</u>

**14 Reserves and retained earnings**

*Movements in reserves*

Reserves at the beginning of the year	2,115,148	2,447,919
Fund For New Research Reserve transfers	(181,840)	(19,220)
Beneficiary Fund Reserve transfers	2,514	(20,152)
OASIS Initiative Reserve transfers	(519,755)	(293,399)
Reserves at the end of the financial year	<u>1,416,067</u>	<u>2,115,148</u>

Reserves have been established for the purpose of allocating accumulating funds received by ANZGOG for the conduct of clinical trials directly related to specific gynaecological cancers and for other research related initiatives. Currently the majority of funds held in Reserves have been committed by the Directors to specific research projects or initiatives. The balances in reserves are drawn down as the research and other projects progress to the extent the Reserve balances allow.

Funds are reserved for projects supporting ANZGOG's purpose including:

- Special project beneficiary funds including Ovarian Cancer Foundation of New Zealand
- OASIS Initiative commitments
- Fund for New Research Grant - multiple commitments

*Movements in retained earnings*

Retained earnings at the beginning of the financial year	2,217,291	1,818,387
Surplus / (deficit) for the year	(710,686)	66,133
Transfer to reserves	(80,217)	(80,628)
Transfer from reserves	779,298	413,399
Retained earnings at the end of the financial year	<u>2,205,686</u>	<u>2,217,291</u>

# Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

## 15 Related party transactions

### *Directors' compensation*

The directors act in an honorary capacity and receive no compensation for their services.

### *Key management personnel*

Disclosures in relation to key management personnel are set out in Note 12.

### *Receivable from / payable to related parties*

There were no receivables, payables or loans to or from related parties at 30 June 2025 (2024: nil).

## 16 Events subsequent to year end

No other matters or circumstances have arisen since the end of the financial year which may significantly affect the operations of the company, the results of those operations, or the state of affairs of the company in subsequent years.

## 17 Contingent liabilities and capital commitments

The company has no contingent liabilities as at year end (2024: nil).

	2025	2024
	\$	\$
<i>Operating lease commitments</i>		
Payable - minimum lease payments		
Less than one year	4,712	4,712
Between one and five years	-	-
	<u>4,712</u>	<u>4,712</u>
	<u>4,712</u>	<u>4,712</u>
The lease expense for the year is \$11,095 (2024: \$11,095).		
<i>Other commitments</i>		
Less than one year	-	-
	<u>-</u>	<u>-</u>
	<u>-</u>	<u>-</u>

## Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

Notes to and forming part of the financial statements  
for the year ended 30 June 2025

### 18 Members' guarantee

The company is limited by guarantee. In the event of the company being wound up, each member of the company undertakes to contribute to the assets of the company an amount not exceeding \$100 for payment of the debts and liabilities of the company including the costs of the winding up. This undertaking continues for one year after a member ceases to be a member of the company.

At 30 June 2025 the number of members was 1,496 (2024: 1,457)

### 19 Core activities

ANZGOG's core activities include conducting and promoting cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynaecological cancers.

Total expenses	6,079,149	4,737,581
Trial and education expenses	4,167,572	3,049,261
Trial and education expenses as a percentage of total expenses	69%	64%

2025  
\$

2024  
\$

### 20 Information furnished under the Charitable Fundraising Act

The following information is a requirement of the Charitable Funds Act.

Fundraising activities	888,698	679,861
Fundraising expenses	(275,664)	(146,629)
Net surplus from fundraising appeals	613,034	533,232

The net surplus is applied toward ANZGOG's charitable objectives.

### 21 Company details

The registered office and principle place of business of the company is:

Level 6, Lifehouse Building  
119-143 Missenden Road, Camperdown, NSW 2050

## Australia New Zealand Gynaecological Oncology Group

Annual financial report - 30 June 2025

### Directors' declaration

In the directors' opinion:

- The attached financial statements and notes thereto comply with the Australian Charities and Not-for-profits Commission Act 2012, the Australian Accounting Standards - Simplified Disclosure Requirements, the Australian Charities and Non-for-profits Commission Regulations 2013 and other mandatory professional reporting requirements;
- The provision of the Charitable Fundraising Act 1991 and the regulations under the Act and the conditions attached to the authority have been complied with for the year ended 30 June 2025;
- The attached financial statements and notes thereto give a true and fair view of the company's financial position as at 30 June 2025 and of its performance for the financial year ended on that date; and
- There are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

Signed in accordance with a resolution of the Board of Directors.

On behalf of the directors



Professor Clare Scott AM  
Chair

Sydney, 25 September 2025

## INDEPENDENT AUDITOR'S REPORT

To the Members of Australia New Zealand Gynaecological Oncology Group.

### *Report on the Audit of the Financial Report*

#### *Opinion*

We have audited the financial report of Australia New Zealand Gynaecological Oncology Group, which comprises the statement of financial position as at 30 June 2025, the statement of comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statement, including material accounting policy information, and the directors' declaration.

In our opinion, the accompanying financial report of Australia New Zealand Gynaecological Oncology Group is in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (a) giving a true and fair view of the Company's financial position as at 30 June 2025 and of its financial performance for the year ended on that date; and
- (b) complying with Australian Accounting Standards – simplified disclosures and Division 60 of the *Australian Charities and Not-for-profits Commission Regulations 2022*.

#### *Basis for opinion*

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Company in accordance with the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### *Other Information*

The Directors are responsible for the other information. The other information comprises the information included in the Director's Report for the year ended 30 June 2025, but does not include the financial report or our auditor's report thereon.

Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon.

#### **Brendale**

Unit 3, 27 South Pine Rd  
Brendale, QLD 4500  
**+61 (7) 3490 9988**

#### **Sunshine Coast**

Level 2, 2 Innovation Parkway  
Birtinya, QLD 4575  
**+61 (7) 5301 9957**

#### **Brisbane**

Level 11, 300 Ann Street  
Brisbane, QLD 4001  
**+61 (7) 3490 9988**

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### *Responsibilities of the Directors for the Financial Report*

The Directors of the Company are responsible for the preparation and fair presentation of the financial report in accordance with Australian Accounting Standards and the ACNC Act, and for such internal control as the Directors determine is necessary to enable the preparation of the financial report that is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing as applicable, matters relating to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so.

The Directors are responsible for overseeing the Company's financial reporting process.

#### *Auditor's Responsibilities for the Audit of the Financial Report*

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of Directors' use of the going concern basis of accounting and based, on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### *Independence*

We confirm that the independence declaration required by the ACNC Act, which has been given to the Directors of Australia New Zealand Gynaecological Oncology Group, would be in the same terms if given to the Directors as at the time of this auditor's report.



.....  
Jason Croston

**Managing Partner**

**SRJ Walker Wayland (Audit Services) Pty Ltd**

Date: 10 October 2025

Address: Unit 3, 27 South Pine Road, BRENDALE QLD 4500